Literature DB >> 18640814

Usefulness and applicability of femorofemoral crossover bypass grafting.

Geertje Thuijls1, L W van Laake, M S Lemson, P J Kitslaar.   

Abstract

We examined the usefulness of femorofemoral crossover bypass grafting (FFC) and factors influencing its outcome by retrospectively analyzing all FFCs performed in our hospital over a 5-year period, focusing on both patency rates and clinical efficacy. For 95 patients Kaplan-Meier patency rates were calculated (follow-up 40.4 +/- 3.0 months). Clinical outcome was defined according to Rutherford's standardized categories. The influence of cardiovascular risk factors and technical characteristics on outcome was determined. Clinical status of the limb remained improved in 89%. One- and 5-year primary, primary assisted, and secondary patency rates were 88.2% and 57.3%, 90.6% and 62.4%, and 92.6% and 68.1%, respectively. Clinical outcome of the limb was better in patients with <50% stenosis in the femoral arteries preoperatively (p = 0.033). No predictors for patency rates were identified. FFCs are effective in the medium long term for patients in all age categories independently of cardiovascular risk factors. The best predictor of clinical outcome is the preoperative degree of stenosis, with a better outcome for patients affected by <50% stenosis. Success of FFC cannot be reliably measured by graft patency alone but should be assessed by combining patency rates and clinical outcome according to standardized categories.

Entities:  

Mesh:

Year:  2008        PMID: 18640814     DOI: 10.1016/j.avsg.2008.04.002

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  2 in total

Review 1.  Current state of diagnosis and management of critical limb ischemia.

Authors:  Dan Clair; Samir Shah; John Weber
Journal:  Curr Cardiol Rep       Date:  2012-04       Impact factor: 2.931

2.  Long Term Outcomes of Femorofemoral Crossover Bypass Grafts.

Authors:  Keun-Myoung Park; Yang-Jin Park; Young-Wook Kim; Dongho Hyun; Kwang Bo Park; Young-Soo Do; Dong-Ik Kim
Journal:  Vasc Specialist Int       Date:  2017-06-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.